Welcome to our dedicated page for Neurometrix news (Ticker: NURO), a resource for investors and traders seeking the latest updates and insights on Neurometrix stock.
NeuroMetrix Inc (NURO) is a pioneer in wearable neuromodulation and diagnostic technologies for chronic pain and diabetic neuropathy. This news hub provides investors and healthcare professionals with timely updates on the company's advancements in bioelectrical medicine, regulatory milestones, and strategic initiatives.
Discover official press releases covering product launches, clinical study results, and financial performance. Our curated collection includes updates on NURO's Quell® wearable therapy platform, DPNCheck® diagnostic devices, and innovations in digital health integration. The page serves as a comprehensive resource for understanding the company's progress in addressing chronic conditions through non-invasive solutions.
Key content areas include earnings announcements, FDA regulatory updates, partnership developments, and research breakthroughs. All materials are sourced directly from company filings and verified industry publications to ensure accuracy. Bookmark this page for streamlined access to NeuroMetrix's latest developments in neurostimulation technology and diagnostic screening tools.
NeuroMetrix, Inc. (Nasdaq: NURO) announced FDA Breakthrough Designation for its Quell® device aimed at treating fibromyalgia in adults. Fibromyalgia impacts 5 to 15 million Americans with chronic pain, fatigue, and mood disturbances. Quell, a wearable neurostimulator, operates with a custom microchip for precise nerve stimulation and has shown a 56% improvement in health-related quality of life for users in trials. The FDA's designation enables priority review, expediting the device's market entry. NeuroMetrix plans a regulatory filing to launch Quell in the second half of next year.
NeuroMetrix, Inc. (Nasdaq: NURO) announced it will release its 2021 second quarter financial results on July 22, 2021, before market opening. A conference call will follow at 8:00 a.m. ET on the same day to discuss these results and related business developments. Investors can access the call by dialing 844-787-0799 in the U.S. or 661-378-9630 internationally, using confirmation code 4269315. Financial reports will be available on the company's website under 'Investor Relations'.
NeuroMetrix (NASDAQ: NURO) announced a clinical trial utilizing Quell technology to evaluate the effectiveness of transcutaneous electrical nerve stimulation (TENS) for pain relief in patients with neuromyelitis optica spectrum disorder (NMOSD). Led by Dr. Michael Levy at Massachusetts General Hospital, the trial will enroll 46 patients, assessing pain intensity changes over 8 weeks. Quell is a non-invasive TENS platform, aiming to address chronic pain where current treatments fall short. The trial highlights Quell's investigational use, pending FDA review for NMOSD treatment.
NeuroMetrix, Inc. (Nasdaq: NURO) announced top-line results from a randomized controlled trial of its Quell device for fibromyalgia. The trial involved 119 subjects at Brigham and Women's Hospital, revealing no significant treatment difference in the primary endpoint of Patient Global Impression of Change (PGIC), p=0.351. However, subgroup analysis showed strong improvements for those with elevated pain sensitivity (active 4.24 vs. sham 3.09, p=0.032). Other positive secondary endpoints included a significant decrease in the FIQR Total Score, p=0.001, with minimal minor adverse events. Quell remains investigational for fibromyalgia.
NeuroMetrix, Inc. (Nasdaq: NURO) reported Q1 2021 financial results with revenue at $2.2 million, a 19% sequential increase from Q4 2020, and stable year-over-year compared to Q1 2020. The gross margin improved to 73.3%, up 190 basis points from the prior year. The net loss decreased significantly to $60 thousand, or $0.02 per share, compared to a loss of $657 thousand, or $0.45 per share, in Q1 2020. Notably, the domestic Medicare Advantage business was a key revenue contributor, and the Company launched new software for DPNCheck, further driving growth.
NeuroMetrix plans to release its 2021 Q1 financial results on April 22, 2021, before market opening. A conference call is scheduled for 8:00 a.m. Eastern Time on the same day to discuss these results and related business developments. Interested parties in the U.S. can join by calling 844-787-0799 with confirmation code 9554608, while international participants can use 661-378-9630. The earnings press release will be accessible on the Company’s website under the 'Investor Relations' tab.
NeuroMetrix, Inc. (Nasdaq: NURO) reported Q4 2020 revenue of $1.8 million, a 6% increase from $1.7 million in Q4 2019, despite ongoing challenges from the COVID-19 pandemic. Gross margins improved to 73.7%, up from 62.2% the previous year. Operating expenses decreased by 39% to $1.7 million. The net loss narrowed to $0.3 million from $1.1 million in Q4 2019. For the year, revenues declined to $7.4 million from $9.3 million in 2019, but gross profit increased significantly. The company remains focused on growth and efficiency improvements.
NeuroMetrix (NURO) will release its Q4 and full-year 2020 financial results on January 28, 2021, before market openings. A conference call is set for 8:00 a.m. ET that same day to discuss these results and related business developments. Investors can access the call by dialing specific numbers for domestic and international participants. The call will be replayed for a week post-event. NeuroMetrix specializes in innovative medical devices for nervous system disorders, offering products like DPNCheck®, ADVANCE™, and Quell®.
NeuroMetrix (NURO) reported Q3 2020 financial highlights, with revenues at $2.0 million, similar to Q3 2019. Gross margin improved to 73.6%, up 17.4 percentage points from the previous year. Record sales were noted for DPNCheck®, driven mainly by the Medicare Advantage sector and support from a recent collaboration with Biomedix. The Quell® Apple Watch® app launched in September, enhancing user experience. Operating expenses decreased by 32.1%, and net loss reduced to $0.3 million from $1.4 million year-over-year. The company maintains a cash reserve of $4.9 million.
NeuroMetrix, Inc. (Nasdaq:NURO) plans to report its Q3 2020 financial results on October 22, 2020, before market opening. A conference call will follow at 8:00 a.m. ET to discuss the results and relevant business updates. Dial-in details include 844-787-0799 for the U.S. and 661-378-9630 internationally, with confirmation code 9786945. The earnings release and financial statements will be available on the company's website. NeuroMetrix specializes in neurostimulation-based medical devices and has three FDA-cleared products.
